Amritha Suresh, Muhil Vannan, Dhanya Kumaran, Zeynep H. Gümüs, Priya Sivadas, Elango Erode Murugaian, Vikram Kekatpure, Subramanian Iyer, Kumarasamy Thangaraj, Moni Abraham Kuriakose, "Resistance/Response Molecular Signature for Oral Tongue Squamous Cell Carcinoma", Disease Markers, vol. 32, Article ID 926703, 14 pages, 2012. https://doi.org/10.3233/DMA-2012-0860
Resistance/Response Molecular Signature for Oral Tongue Squamous Cell Carcinoma
Worldwide, the incidence of oral tongue cancer is on the rise, adding to the existing burden due to prevailing low survival and high recurrence rates. This study uses high-throughput expression profiling to identify candidate markers of resistance/response in patients with oral tongue cancer. Analysis of primary and post-treatment samples (12 tumor and 8 normal) by the Affymetrix platform (HG U133 plus 2) identified 119 genes as differentially regulated in recurrent tumors. The study groups had distinct profiles, with induction of immune response and apoptotic pathways in the non-recurrent and metastatic/invasiveness pathways in the recurrent group. Validation was carried out in tissues by Quantitative Real-Time PCR (QPCR) (n=30) and immunohistochemistry (IHC) (n=35) and in saliva by QPCR (n=37). The markers, COL5A1, HBB, IGLA and CTSC individually and COL5A1 and HBB in combination had the best predictive power for treatment response in the patients. A subset of markers identified (COL5A1, ABCG1, MMP1, IL8, FN1) could be detected in the saliva of patients with oral cancers with their combined sensitivity and specificity being 0.65 and 0.87 respectively. The study thus emphasizes the extreme prognostic value of exploring markers of treatment resistance that are expressed in both tissue and saliva.
Copyright © 2012 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.